‘We're stuck with this house': Utah family says their $860K new build cracked, flooded and forced them out
Drawn in by the stunning mountain views and the promise of a new life, they purchased a brand-new home for $860,000 from Toll Brothers, a developer that calls itself 'America's luxury home builder.'
But that dream home quickly turned into a nightmare, they told FOX 13. Within 30 days of moving in, the Schmidts say they noticed cracks in the drywall. By the second month, doors were no longer opening or closing properly as the house continued to settle.
Then, while they were away, a pipe above the stove burst, flooding the house and forcing the family into a rental. What they thought would be a three-month displacement turned into an 18-month ordeal.
I'm 49 years old and have nothing saved for retirement — what should I do? Don't panic. Here are 6 of the easiest ways you can catch up (and fast)
Thanks to Jeff Bezos, you can now become a landlord for as little as $100 — and no, you don't have to deal with tenants or fix freezers. Here's how
Want an extra $1,300,000 when you retire? Dave Ramsey says this 7-step plan 'works every single time' to kill debt, get rich in America — and that 'anyone' can do it
Despite the home being under warranty, the Schmidts say the timeline for repairs dragged on without any guaranteed deadlines. During the entire time Toll Brothers was working on the home, the family lived in a series of short-term rentals.
'We're building tunnels under oceans,' Jessica Schmidt told FOX 13. 'How hard is it to make sure this house doesn't slide down a river?'
Neal Schmidt began documenting the delays on social media, even tagging Toll Brothers. Other homeowners in the neighborhood also reported issues, but only one neighbor's home was bought back by the builder. When the Schmidts asked for the same, they say the company flatly refused.
In the end, the couple reached a private settlement with Toll Brothers and removed the social media posts. But the emotional and financial damage remained. 'We're stuck with this house that we know is never going to be worth what it could be,' Jessica said.
The Schmidts' story is far from unique in Utah. In a 2023 case that drew national attention, homes in a Draper, Utah neighborhood slid down a mountainside after being built on unstable ground.
FOX 13 has investigated and found a common thread: Utah's laws offer little protection for homebuyers facing construction defects.
'There's a fair chance that when you buy a home in Utah,' said John Morris, an attorney who has represented Utah homeowners, 'and there are problems with that home, you really will have no avenue for recovery. Zero.'
Read more: No millions? No problem. With as little as $10, here's of diversified assets usually only available to major players
Utah's rapid growth has fueled a boom in new home construction, but legal protections haven't kept pace. Unlike some states, which have licensing boards to investigate poor workmanship, Utah has no agency tasked with enforcing quality standards in new builds. The Division of Professional Licensing only penalizes builders for issues like working without permits, not for construction flaws that emerge after closing.
Most builders offer warranties, but those warranties often favor the builder. They may not guarantee repair timelines and can exclude major problems. They also tend to limit what a homeowner can do legally, sometimes requiring arbitration instead of lawsuits, which can restrict your options for getting meaningful compensation.
And while homeowners technically have six years to sue over safety-related defects, those cases are costly, time-consuming and rarely pay off. Utah doesn't allow most homeowners to recover attorney's fees in these lawsuits. So what can Utah buyers do?
Research the builder: Read reviews and look into past complaints or lawsuits.
Get a serious inspection: Don't rely on a basic $150 inspection or city approval. Hire someone who can assess your home's structural integrity and moisture protection.
Read the contract closely: Know what's covered in the warranty, how long it lasts, and whether it includes binding arbitration clauses that limit your legal rights.
File warranty claims early and in writing: Don't wait — most builders won't act unless you document the issue and make a formal claim.
Document everything: Photos, videos, repair requests, and email chains can all support your case if issues escalate.
Use public pressure: If you get nowhere with the builder, consider online reviews or reaching out to local reporters. One homeowner said that's what finally got the company's attention.
Understand your HOA rules: If your neighborhood has one, you may be financially responsible for repairs to shared infrastructure, even if it was the developer's fault.
Until Utah lawmakers pass stronger protections for buyers, the burden of making sure a home is safe and sound falls largely on the homeowner. And that means doing your homework long before the keys are in your hand.
This tiny hot Costco item has skyrocketed 74% in price in under 2 years — but now the retail giant is restricting purchases. Here's how to buy the coveted asset in bulk
Robert Kiyosaki warns of a 'Greater Depression' coming to the US — with millions of Americans going poor. But he says these 2 'easy-money' assets will bring in 'great wealth'. How to get in now
Rich, young Americans are ditching the stormy stock market — here are the alternative assets they're banking on instead
Here are 5 'must have' items that Americans (almost) always overpay for — and very quickly regret. How many are hurting you?
Money doesn't have to be complicated — sign up for the free Moneywise newsletter for actionable finance tips and news you can use.
This article provides information only and should not be construed as advice. It is provided without warranty of any kind.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Why Google should 'walk away' from Waymo
Needham & Company senior media and internet analyst Laura Martin joins Market Domination with Josh Lipton to explain why Alphabet (GOOG, GOOGL) should ditch Waymo and focus on generative artificial intelligence (AI) instead. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Related videos The £70bn pension tax raid Reeves may not be able to resist 10 shares I wouldn't want to hold in a stock market crash After falling 16% in a day, this stock's on my list of shares to buy in August This FTSE 250 trust is easily beating the global index in 2025. Time to buy? Sign in to access your portfolio
Yahoo
15 minutes ago
- Yahoo
EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million
EMCOR Group recently announced a regular quarterly cash dividend of $0.25 per common share, to be paid on July 31, 2025. This steady dividend approach aligns with the company's robust quarterly performance, which saw net income rise to $241 million and EPS increase substantially year-over-year. Additionally, the ongoing share buyback program has strengthened shareholder returns. Despite the broader market's moderate growth of 1.4% over the past week and 17% over the past year, EMCOR's notable share repurchases and solid financial outcomes appear to have amplified investor confidence, contributing to the company's impressive 55% stock price surge last quarter. We've spotted 1 risk for EMCOR Group you should be aware of. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. EMCOR Group's recent announcement of a quarterly dividend and the implementation of its share buyback program underline its commitment to enhancing shareholder returns. Despite a potential downside to the current share price of US$635.06, which exceeds the consensus analyst price target of US$549.57 by 13.46%, these actions could continue to buoy investor confidence. The company's performance over the past five years, with a total return exceeding 844.60%, showcases its robust long-term trajectory. In the last year, EMCOR's share performance exceeded both the broader market's 17.2% and the US Construction industry's 54.2% return, highlighting its strong standing relative to peers. The successful integration of acquisitions and strategic diversification into sectors like data centers and healthcare is anticipated to impact future revenue positively. This, coupled with operational efficiencies and strong revenue collaboration, may reinforce earnings projections. However, EMCOR's earnings forecasts of a 6.2% annual growth rate lag behind the broader market's 14.9% forecast, which could present challenges in meeting broader industry expectations. The company's impressive share price rise of 55% last quarter signals optimism, though its current value being above the target may indicate overvaluation concerns. Nevertheless, the consistent cash flow and healthy margins underscore its potential resilience against margin pressures, supply chain challenges, and other economic uncertainties. As analysts estimate revenue growth to 7.9% annually over the next three years, any tangible improvement in operational metrics could shift the valuation outlook positively. Unlock comprehensive insights into our analysis of EMCOR Group stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include EME. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@